SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Instruments Regulatory News (OXIG)

Share Price Information for Oxford Instruments (OXIG)

Share Price is delayed by 15 minutes
Get Live Data
2,878.00    130.00 (4.73%)
Bid:
2,846.00
Ask:
2,862.00
Spread: 16.00 (0.562%)
Market Cap: £1.59b
OXIG Live PriceLast checked at - London Stock Exchange

Intraday Oxford Instruments Share Chart

Trading Update

16 Apr 2025 07:00

RNS Number : 1833F
Oxford Instruments PLC
16 April 2025
 

 

 

Oxford Instruments plc

Full-year trading update - 16 April 2025

 

Strong H2 delivered - full-year trading in line with expectations

Good progress on execution of the strategy

 

 

Oxford Instruments plc, a leading provider of scientific technology and expertise to academic and commercial partners, is today issuing a trading update for the year ended 31 March 2025.

 

We have delivered a strong full-year performance, in line with expectations. This has been underpinned by continued momentum in order intake and good progress on the execution of our strategy. We are seeing the benefits of the actions we have taken to drive operational excellence, improve commercial execution, and bring a greater focus on our costs.

 

Revenue growth in the second half has been strong, as anticipated, resulting in full-year revenue growth expected to be around +9% at constant currency1 (+6% at actual rates) versus the prior year. Demand has remained healthy, with 3% year-on-year order growth at constant currency.

 

Full-year adjusted operating profit2 is expected to be up around 13% on a constant currency basis (3% at actual rates), in line with market expectations. Group constant currency adjusted operating margin is expected to be around 17.8% (16.5% at actual rates), up 70 bps year on year with margin progress in both divisions.

 

Our Imaging & Analysis division, which represents two-thirds of Group revenue and around 90% of its operating profit, has performed well, growing both orders and revenue whilst maintaining its excellent operating margin above 24% at constant currency. Semiconductor revenues have grown strongly and, along with materials analysis, have offset continuing softness in the healthcare and life science end market.

 

Our Advanced Technologies division has delivered strong double digit constant currency revenue growth. As anticipated, we delivered a number of large customer orders in our quantum business which, together with operational improvements, resulted in a return to profitability. We have also continued to grow our compound semiconductor business in its new facility and increase our Tier 1 customer base, achieving both double-digit revenue growth and a margin improvement.

Richard Tyson, CEO, commented:

 "I am very pleased with how the team have embraced the strategy, delivering strong results despite the macro volatility seen in H2 and the execution of our pivot away from certain market segments in China."

"We continue to closely monitor and adapt to the potential impacts of macro events. Oxford Instruments' growth and resilience is underpinned by our diversified portfolio of market-leading technologies, deployed in multiple structurally growing sectors across all the major geographies. In addition, there are significant opportunities within our own control, as we accelerate our operational transformation programme, work to simplify and standardise our business, and drive a continued critical focus on product profitability."

Oxford Instruments management will present its full-year results to analysts and investors at Deutsche Numis, 45 Gresham Street, London EC2V 7BF, on 10 June 2025.

 

Notes:

1. Constant currency numbers are prepared on a month-by-month basis using the translational and transactional exchange rates which prevailed in the previous year rather than the actual exchange rates which prevailed in the year. Transactional exchange rates include the effect of our hedging programme.

2. Adjusted items exclude the amortisation and impairment of acquired intangible assets, acquisition items, business reorganisation costs, other significant non‑recurring items, and the mark-to-market movement of financial derivatives.

 

The financial information in this trading update is unaudited.

LEI: 213800J364EZD6UCE231

 

Enquiries:

Oxford Instruments plc

Richard Tyson, Chief Executive Officer

Paul Fry, Chief Financial Officer

Stephen Lamacraft, Head of Investor Relations Stephen.lamacraft@oxinst.com 

 

MHP Group

Katie Hunt/Tim Rowntree/ 07710 117517

Veronica Farah oxfordinstruments@mhpgroup.com

Notes to Editors

About Oxford Instruments plc

Oxford Instruments provides academic and commercial organisations worldwide with market-leading scientific technology and expertise across its key market segments: materials analysis, semiconductors, and healthcare & life science. Innovation is the driving force behind Oxford Instruments' growth and success, supporting its core purpose to accelerate the breakthroughs that create a brighter future for our world. The vigorous search for new ways to make our world greener, healthier and more productive is driving unprecedented levels of R&D investment in new materials and techniques to support productivity and decarbonisation worldwide, creating a significant opportunity for Oxford Instruments to grow. Oxford Instruments holds a unique position to anticipate global drivers and connect academic researchers with commercial applications engineers, acting as a catalyst that powers real world progress. Founded in 1959 as the first technology business to be spun out from Oxford University, Oxford Instruments is now a global, FTSE250 company listed on the London Stock Exchange (OXIG). For more information, visit www.oxinst.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPKPBDFBKDPQD
Date   Source Headline
3rd Jun 20248:22 amPRNTotal Voting Rights
31st May 20248:50 amPRNHolding(s) in Company
13th May 20241:15 pmPRNDirector/PDMR Shareholding
1st May 202410:12 amRNSTotal Voting Rights
24th Apr 20244:31 pmPRNHolding(s) in Company
24th Apr 20244:29 pmPRNHolding(s) in Company
16th Apr 20247:00 amRNSTrading Update
11th Apr 202412:54 pmPRNDirector/PDMR Shareholding
2nd Apr 202410:32 amPRNTotal Voting Rights
20th Mar 20244:26 pmPRNDirector/PDMR Shareholding
12th Mar 20248:30 amPRNDirector/PDMR Shareholding
1st Mar 20248:00 amPRNTotal Voting Rights
28th Feb 202411:25 amPRNHolding(s) in Company
12th Feb 20244:15 pmPRNDirector/PDMR Shareholding
1st Feb 20249:10 amPRNTotal Voting Rights
19th Jan 202411:30 amPRNHolding(s) in Company
11th Jan 20244:25 pmPRNDirector/PDMR Shareholding
10th Jan 20247:00 amRNSAcquisition of First Light Imaging SAS
2nd Jan 20241:31 pmPRNBlocklisting - Interim Review
2nd Jan 20241:19 pmPRNTotal Voting Rights
12th Dec 20239:00 amPRNDirector/PDMR Shareholding
1st Dec 20239:00 amPRNTotal Voting Rights
22nd Nov 20232:01 pmPRNAppointment of Independent Non-Executive Director
15th Nov 20234:42 pmPRNDirector/PDMR Shareholding
15th Nov 202312:29 pmPRNDirector/PDMR Shareholding
14th Nov 20237:00 amRNSHalf-Year Results
13th Nov 20231:37 pmPRNDirector/PDMR Shareholding
1st Nov 20239:00 amPRNTotal Voting Rights
17th Oct 20234:13 pmPRNHolding(s) in Company
12th Oct 20234:03 pmPRNDirector/PDMR Shareholding
12th Oct 20237:00 amRNSHalf Year Trading Update
11th Oct 20239:32 amPRNDirector/PDMR Shareholding
2nd Oct 20238:53 amPRNTotal Voting Rights
27th Sep 20234:19 pmPRNDirector/PDMR Shareholding
25th Sep 20234:20 pmPRNDirector/PDMR Shareholding
19th Sep 20231:41 pmPRNAnnual General Meeting 2023 Results
14th Sep 20237:00 amPRNBlock Listing Application
12th Sep 20233:27 pmPRNDirector/PDMR Shareholding
10th Aug 20232:16 pmPRNDirector/PDMR Shareholding
7th Aug 202310:35 amPRNHolding(s) in Company
1st Aug 20232:16 pmRNSTotal Voting Rights
27th Jul 20234:59 pmRNSHolding(s) in Company
27th Jul 20231:51 pmRNSCEO succession update
26th Jul 20235:12 pmRNSDirector/PDMR Shareholding
26th Jul 202311:15 amRNSHolding(s) in Company
25th Jul 202312:44 pmRNSDirector/PDMR Shareholding
20th Jul 202310:23 amPRNPublication of Annual Report and Notice of AGM 2023
10th Jul 20233:26 pmPRNDirector/PDMR Shareholding
6th Jul 20237:00 amRNSAnnual General Meeting: revised date
3rd Jul 20232:37 pmPRNBlocklisting - Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.